Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Niagen Bioscience's Total Assets for the quarter that ended in Mar. 2026 was €98.9 Mil.
During the past 12 months, Niagen Bioscience's average Total Assets Growth Rate was 85.30% per year.
During the past 3 years, the average Total Assets Growth Rate was 7.30% per year.
During the past 5 years, the average Total Assets Growth Rate was 7.00% per year.
During the past 10 years, the average Total Assets Growth Rate was 9.20% per year.
During the past 13 years, Niagen Bioscience's highest 3-Year average Total Assets Growth Rate was 40.10%. The lowest was -7.30%. And the median was 14.60%.
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Niagen Bioscience's Asset Turnover for the quarter that ended in Mar. 2026 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Niagen Bioscience Total Assets Related Terms
Niagen Bioscience Total Assets Historical Data
* Premium members only.
The historical data trend for Niagen Bioscience's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Niagen Bioscience's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Niagen Bioscience (FRA:OCD1) has a Total Assets of €98.9 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Niagen Bioscience and its competitors.
Is Niagen Bioscience's Total Assets too high?
Niagen Bioscience's current Total Assets is €98.9 Mil. Overall, Niagen Bioscience has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Niagen Bioscience's Total Assets compare to LCTX and IFRX?
Niagen Bioscience's Total Assets of €98.9 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Niagen Bioscience and its competitors. Niagen Bioscience's current Total Assets is €98.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Niagen Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Niagen Bioscience (FRA:OCD1) is currently considered Possible Value Trap. The stock's GF Value™ is €3.98, compared to a current price of €2.58 — trading 35.2% below its estimated fair value. The current Total Assets is €98.9 Mil. Niagen Bioscience's overall GF Score™ is 67/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Niagen Bioscience (FRA:OCD1), the current Total Assets is €98.9 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Niagen Bioscience (FRA:OCD1) Overvalued in 2026?
Based on GuruFocus' analysis, Niagen Bioscience stock appears to be undervalued.
The current stock price of €2.58 is trading 35.2% below its estimated GF Value™ of €3.98.
GuruFocus considers Niagen Bioscience to be Possible Value Trap.
Key valuation signals for FRA:OCD1:
Total Assets: €98.9 Mil
GF Value™: €3.98 vs. price of €2.58 (35.2% below fair value)
No single metric tells the full story. See the FRA:OCD1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
67GF Score
Get the complete analysis for FRA:OCD1
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:OCD1 has been successfully added to your 
